NP-1815-PX

Overview

NP-1815-PX is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC 50 of 0.26 μM against human P2X4 receptors. NP-1815-PX specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX selectively blocks smooth muscle contractions induced by ATP, U46619 ( HY-108566 ) and prostaglandin F2α . NP-1815-PX not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS ( HY-W324435 )-induced colitis (such as weight loss and tissue damage). NP-1815-PX exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX is used in studies related to asthma and inflammatory bowel disease (colitis).

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > Prostaglandin Receptor | Products > Signaling Pathways > P2X Receptor | Products > Signaling Pathways > NOD-like Receptor (NLR) | Products > Signaling Pathways > Caspase

Product Information

• Catalog No.: HY-150270
• CAS No.: 1239578-79-0
• Molecular Formula: C21H14N4O3S
• Molecular Weight: 402.43
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source